GlassScriptPhysician profile
Obada Tayyem
NPI 1487006672
$4,834.86
in general payments reported to CMS, 2019-2025
32 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $483 · 2023: $2,300 · 2024: $1,456 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,186 · Education: $47.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,185.94 |
| Education | $47.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.40 | 2022-2025 | Skyrizi, Rinvoq, Viberzi |
| Fresenius Kabi USA, LLC | $608.65 | 2023 | |
| Gilead Sciences, INC. | $458.31 | 2023-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $419.52 | 2023-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $324.02 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.29 | 2022-2024 | Xifaxan, Trulance, Uceris |
| Genzyme Corporation | $250.04 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $193.49 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $187.96 | 2023-2024 | Ocaliva |
| Lilly USA, LLC | $173.17 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $169.13 | 2024 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $162.22 | 2023 | Terlivaz |
| Medtronic, INC. | $127.92 | 2025 | Endoflip |
| Boston Scientific Corporation | $119.30 | 2021 | |
| Pfizer INC. | $116.25 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $108.38 | 2023 | Zeposia |
| Celgene Corporation | $96.27 | 2023-2024 | Zeposia |
| Organon LLC | $71.87 | 2023-2024 | Hadlima |
| Celltrion USA INC. | $47.29 | 2023-2024 | Vegzelma, Yuflyma |
| Ardelyx, INC. | $44.96 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $41.63 | 2022-2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $40.46 | 2022-2023 | Linzess |
| Sandoz INC. | $30.36 | 2024 | Hyrimoz |
| Daiichi Sankyo INC. | $30.01 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $27.41 | 2023-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $25.23 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $20.86 | 2024 | Givlaari |
| Mauna Kea Technologies, INC. | $19.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.22 | 2023 | Cyltezo |
| Ucb, INC. | $14.98 | 2024 | Cimzia |
| Madrigal Pharmaceuticals | $14.73 | 2025 | Rezdiffra |
| Sirtex Medical INC | $2.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obada Tayyem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.